Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | DRP-104 |
| Trade Name | |
| Synonyms | DRP 104|DRP104|Sirpiglenastat |
| Drug Descriptions |
Sirpiglenastat (DRP-104) is the prodrug form of glutamine antagonist, which potentially modulates immune response and inhibits tumor growth (J Immunother Cancer. 2019; 7(Suppl 1): 282, Abs nr: P497). |
| DrugClasses | |
| CAS Registry Number | 2079939-05-0 |
| NCIT ID | C174038 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Atezolizumab + DRP-104 | Atezolizumab DRP-104 | 0 | 1 |
| DRP-104 | DRP-104 | 0 | 2 |
| DRP-104 + Durvalumab | DRP-104 Durvalumab | 0 | 1 |
| DRP-104 + unspecified PD-1 antibody | DRP-104 unspecified PD-1 antibody | 0 | 0 |
| DRP-104 + unspecified PD-L1 antibody | DRP-104 unspecified PD-L1 antibody | 0 | 0 |